141 related articles for article (PubMed ID: 37270068)
1. Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection.
Su S; Xuan Y; Fan X; Bao H; Tang H; Lv X; Ren W; Chen F; Shao Y; Wang T; Wang L
Genomics; 2023 Jul; 115(4):110662. PubMed ID: 37270068
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
3. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
4. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free DNA sequencing for early detection of lung cancer.
Xue R; Yang L; Yang M; Xue F; Li L; Liu M; Ren Y; Qi Y; Zhao J
Expert Rev Mol Diagn; 2023; 23(7):589-606. PubMed ID: 37318381
[TBL] [Abstract][Full Text] [Related]
6. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics.
Wang F; Li X; Li M; Liu W; Lu L; Li Y; Chen X; Yang S; Liu T; Cheng W; Weng L; Wang H; Lu D; Yao Q; Wang Y; Wu J; Wittkop T; Faham M; Zhou H; Hu H; Jin H; Hu Z; Ma D; Cheng X
Clin Chem Lab Med; 2024 Jan; 62(1):168-177. PubMed ID: 37678194
[TBL] [Abstract][Full Text] [Related]
7. A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles.
Kim YJ; Jeon H; Jeon S; Lee SH; Kim C; Ahn JH; Um H; Woo YJ; Jeong SH; Kim Y; Park HY; Oh HJ; Cho HJ; Bae JH; Kim JH; An S; Kang SB; Jho S; Biro O; Kis D; Kim BC; Kim Y; Kim JH; Kim BC; Bhak J; Oh IJ
Mol Cell Probes; 2022 Dec; 66():101873. PubMed ID: 36379302
[TBL] [Abstract][Full Text] [Related]
8. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis.
Moldovan N; van der Pol Y; van den Ende T; Boers D; Verkuijlen S; Creemers A; Ramaker J; Vu T; Bootsma S; Lenos KJ; Vermeulen L; Fransen MF; Pegtel M; Bahce I; van Laarhoven H; Mouliere F
Cell Rep Med; 2024 Jan; 5(1):101349. PubMed ID: 38128532
[TBL] [Abstract][Full Text] [Related]
9. Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection.
Bao H; Wang Z; Ma X; Guo W; Zhang X; Tang W; Chen X; Wang X; Chen Y; Mo S; Liang N; Ma Q; Wu S; Xu X; Chang S; Wei Y; Zhang X; Bao H; Liu R; Yang S; Jiang Y; Wu X; Li Y; Zhang L; Tan F; Xue Q; Liu F; Cai S; Gao S; Peng J; Zhou J; Shao Y
Mol Cancer; 2022 Jun; 21(1):129. PubMed ID: 35690859
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
[TBL] [Abstract][Full Text] [Related]
11. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing.
van der Pol Y; Tantyo NA; Evander N; Hentschel AE; Wever BM; Ramaker J; Bootsma S; Fransen MF; Lenos KJ; Vermeulen L; Schneiders FL; Bahce I; Nieuwenhuijzen JA; Steenbergen RD; Pegtel DM; Moldovan N; Mouliere F
EMBO Mol Med; 2023 Dec; 15(12):e17282. PubMed ID: 37942753
[TBL] [Abstract][Full Text] [Related]
12. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma.
Ma X; Chen Y; Tang W; Bao H; Mo S; Liu R; Wu S; Bao H; Li Y; Zhang L; Wu X; Cai S; Shao Y; Liu F; Peng J
J Hematol Oncol; 2021 Oct; 14(1):175. PubMed ID: 34702327
[TBL] [Abstract][Full Text] [Related]
13. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
Helzer KT; Sharifi MN; Sperger JM; Shi Y; Annala M; Bootsma ML; Reese SR; Taylor A; Kaufmann KR; Krause HK; Schehr JL; Sethakorn N; Kosoff D; Kyriakopoulos C; Burkard ME; Rydzewski NR; Yu M; Harari PM; Bassetti M; Blitzer G; Floberg J; Sjöström M; Quigley DA; Dehm SM; Armstrong AJ; Beltran H; McKay RR; Feng FY; O'Regan R; Wisinski KB; Emamekhoo H; Wyatt AW; Lang JM; Zhao SG
Ann Oncol; 2023 Sep; 34(9):813-825. PubMed ID: 37330052
[TBL] [Abstract][Full Text] [Related]
14. Integrated fragmentomic profile and 5-Hydroxymethylcytosine of capture-based low-pass sequencing data enables pan-cancer detection via cfDNA.
Zhang Z; Pi X; Gao C; Zhang J; Xia L; Yan X; Hu X; Yan Z; Zhang S; Wei A; Guo Y; Liu J; Li A; Liu X; Zhang W; Liu Y; Xie D
Transl Oncol; 2023 Aug; 34():101694. PubMed ID: 37209526
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic analysis of cell-free DNA by fragmentomic profiling.
Zhou Q; Kang G; Jiang P; Qiao R; Lam WKJ; Yu SCY; Ma ML; Ji L; Cheng SH; Gai W; Peng W; Shang H; Chan RWY; Chan SL; Wong GLH; Hiraki LT; Volpi S; Wong VWS; Wong J; Chiu RWK; Chan KCA; Lo YMD
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2209852119. PubMed ID: 36288287
[TBL] [Abstract][Full Text] [Related]
16. Systematic biases in reference-based plasma cell-free DNA fragmentomic profiling.
Liu X; Yang M; Hu D; An Y; Wang W; Lin H; Pan Y; Ju J; Sun K
Cell Rep Methods; 2024 Jun; ():100793. PubMed ID: 38866008
[TBL] [Abstract][Full Text] [Related]
17. Cell-free DNA methylation in the clinical management of lung cancer.
Ezegbogu M; Wilkinson E; Reid G; Rodger EJ; Brockway B; Russell-Camp T; Kumar R; Chatterjee A
Trends Mol Med; 2024 May; 30(5):499-515. PubMed ID: 38582623
[TBL] [Abstract][Full Text] [Related]
18. Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies.
Jiang P; Chan KCA; Lo YMD
J Hepatol; 2019 Aug; 71(2):409-421. PubMed ID: 31004682
[TBL] [Abstract][Full Text] [Related]
19. Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction.
Xu J; Chen H; Fan W; Qiu M; Feng J
J Cancer Res Clin Oncol; 2024 Jan; 150(1):7. PubMed ID: 38196018
[TBL] [Abstract][Full Text] [Related]
20. Predicting tumour content of liquid biopsies from cell-free DNA.
Cardner M; Marass F; Gedvilaite E; Yang JL; Tsui DWY; Beerenwinkel N
BMC Bioinformatics; 2023 Sep; 24(1):368. PubMed ID: 37777714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]